NeuroPace, Inc.

NASDAQ:NPCE

Medical - Devices

Healthcare
$8.22 +0.30%

+$0.05 today

Market cap
$283.19M
Beta
1.88
P/E (TTM)
-23.8
EPS (TTM)
-$0.64
52W Low $7.56High $19.60

Volume 0.31M

Average 0.18M

NPCE Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

NeuroPace, Inc.NASDAQ: NPCE

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 81.5% from a year ago

Deferred revenue stood at $126K at the end of Q1 FY2026, down 81.5% from a year earlier and down 10.6% from the prior quarter.

Context

  • Deferred revenue amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -81.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$126K-10.6% QoQ
Last fiscal yearDec 2025
$141K-74.6% YoY
Year agoMar 2025
$680K-81.5% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.5%——
1 year-74.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
141K USD
Year-over-year change
-74.6%

Deferred Revenue vs competitors

How NPCE compares with its peers on the latest reported figures

  • NPCE's Mar 2026 deferred revenue of $126K is the highest of the 2 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.1% of total assets for NPCE, versus a peer median of 0.0%.
NPCE Competitors Peer median
Deferred Revenue for NPCE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NPCENeuroPace, Inc.Mar 2026$126K -81.5%—0.1%
CVRXCVRx, Inc.Mar 2026$0 ——0.0%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding NPCE) $0——0.0%

Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents19.19M6.61M18.06M13.43M21.69M
Short-term Investments96.4M70.8M48.4M39.33M39.37M
Net Receivables7.09M7.48M12.31M12.85M14.68M
Inventory7.82M9.71M11.21M13.38M16.9M
Other Current Assets100K3.11M2.74M2.35M1.44M
Total Current Assets132.82M97.71M92.72M81.34M94.07M
Property, Plant & Equipment (Net)603K15.9M14.41M12.9M11.26M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets143K490K524K413K235K
Total Non-current Assets746K16.39M14.93M13.31M11.49M
Total Assets133.56M114.11M107.65M94.65M105.57M
Account Payables1.38M2.15M2.33M2.95M2.22M
Short-term Debt00002.12M
Tax Payables00000
Deferred Revenue001.09M555K141K
Other Current Liabilities490K0002.85M
Total Current Liabilities9.3M10.98M16.23M15.16M17.81M
Long-term Debt49.85M52.91M56.95M59.53M58.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities911K0000
Total Non-current Liabilities50.76M68.35M70.77M71.48M68.72M
Total Liabilities60.06M79.33M87M86.63M86.53M
Common Stock24K25K28K30K34K
Retained Earnings(423.77M)(470.85M)(503.81M)(530.95M)(552.42M)
Accumulated OCI(272K)(1.11M)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity73.5M34.78M20.65M8.01M19.03M
Total Debt49.85M69.77M72.4M73.34M70.84M
Net Debt30.66M63.16M54.34M59.91M49.15M

NeuroPace, Inc.

NASDAQ:NPCE

Intrinsic Alpha fair value

Locked

Current Price

$8.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.